International Journal of Clinical Research

Objective To analyze patients with cervical cancer combined with autoimmune diseases and then explore the effectiveness of radiation therapy. Methods The patients participating in this study visited from January to December 2021, with a total of 21 patients undergoing analysis of radiation toxicity and immune function changes. Results By analyzing the occurrence of radiation toxicity reactions in 21 patients, it can be seen that 28.6% of patients with grade III-IV acute blood toxicity reactions, including 5 cases with hematological toxicity, 1 case with digestive system toxicity, and 1 case with urinary system toxicity, accounting for 23.8%, 4.8%, and 4.8%, respectively. Two patients experienced chronic digestive toxicity reactions, accounting for 9.55%, and one patient experienced chronic urinary toxicity reactions, accounting for 4.8%. Comparing the peripheral blood T cell subpopulations of 21 patients before and after treatment, it was found that CD4+was 37.96 ± 10.44 before treatment and 35.46 ± 9.17 after treatment. Among them, CD8+was 25.45 ± 5.13 before treatment, changed to 26.00 ± 4.86 after treatment, and CD4+/CD8+was 1.52 ± 0.40 before treatment and 1.39 ± 0.39 after treatment, with no statistically significant difference (p>0.05). Conclusion The use of radiation therapy is tolerable for patients with cervical cancer and autoimmune diseases, and standardized treatment methods should be carried out for patients with radiation indications.

Radiation; Cervical cancer; Clinical effects